

## REFERENCE ARTICLES

### ANIMAL EXPERIMENTS

Berrada, M., Yang, Z., Lehnert, M. ***Sensitization to Radiation from an Implanted <sup>125</sup>I Source by Sustained Intratumoral Release of Chemotherapeutic Drugs.*** Radiation Research: 162: 64-70: 2004.

Biston, M. C., Joubert, A., Adam, J. F., Elleaume, H., Bohic, S., Charvet, A. M., Estève, F., Foray, N., Balosso, J. ***Cure of Fisher Rats Bearing Radioresistant F98 Glioma Treated with cis-Platinum and Irradiated with Monochromatic Synchrotron X-rays.*** Cancer Research: 64:2317-2323: April 2004.

De Stasio, G., Rajesh, D., Casalbore, P., Daniels, M. J., Erhardt, R. J., Frazer, B. H., Wiese, L. M., Richter, K. L., Sonderegger, B. R., Gilbert, B., Schaub, S., Cannara, R. J., Crawford, J. F., et al. ***Are Gadolinium Contrast Agents Suitable for Gadolinium Neutron Capture Therapy?*** Neurological Research: 27: 387-398: June 2005.

De Stasio, G., Rajesh, D., Ford, J. M., Daniels, M. J., Erhardt, R. J., Frazer, B. H., Tyliszczak, T., Gilles, M. K., Conhaim, R. L., Howard, S. P., Fowler, J. F., Estève, F., Mehta, M. P. ***Motexafin-Gadolinium Taken Up In vitro by at Least 90% of Glioblastoma Cell Nuclei.*** Clin Cancer Res 2006: 12(1): 206-213: January 1, 2006.

Hielscher, A. ***Optical Tomographic Imaging of Small Animals.*** Current Opinion in Biotechnology 2005: 16: 79-88: 2005.

Kinsella, T. J., Vielhuber, K. A., Kunugi, K. A., Schupp, J., Davis, T. W., Sands, H. ***Preclinical Toxicity and Efficacy Study of a 14-day Schedule of Oral 5-Iodo-2-pyrimidinone-2'-deoxyribose as a Prodrug for 5-Iodo-2' deoxyuridine Radiosensitization in U251 Human Glioblastoma Xenografts<sup>1</sup>.*** Clin Cancer Res 2000: 6:1468-1475: April 2000.

Laster, B., Dixon, D., Feldman, J., Seror, V., Sheleg, U., Goldbart, Z., Novick, S., Kalef-Ezra, J. ***Photon Activation Therapy with <sup>103</sup>Pd seeds and PtTMPyP4.*** Corresponding author email: [blaster@bgu.ac.il](mailto:blaster@bgu.ac.il).

Takada, K., Kawamura, T., Inai, M., Masuda, S., Oka, T., Yoshikawa, Y., Shibata, N., Yoshikawa, H., Ike, O., Wada, H., Hitomi, S. ***Pharmacokinetics of Cisplatin in Albuminemic Rats.*** Biopharm. Drug Dispos.: 20: 421-428: 1999.

Waters, D. J., Wildasin, K. ***Cancer Clues from Pet Dogs.*** Scientific American: 95-101: December 2006.

## CELLS

Corde, S., Balosso, J., Elleaume, H., Renier, M., Joubert, A., Biston, M. C., Adam, J. F., Charvet, A. M., Brochard, T., Le Bas, J. F., Estève, F., Foray, N. ***Synchrotron Photoactivation of Cisplatin Elicits an Extra Number of DNA Breaks That Stimulate RAD51-mediated Repair Pathways.*** Cancer Research: **63**: 3221-3227: June 15, 2003.

Diggle, C. P., Bentley, J., Knowles, M. A., Kiltie, A. E. ***Inhibition of Double-Strand Break Non-Homologous End-Joining by Cisplatin Adducts in Human Cell Extracts.*** Nucleic Acids Research: **33(8)**: 2531-2539: 2005.

Furusawa, Y., Maezawa, H., Suzuki, K., Yamamoto, Y., Kobayashi, K., Hieda, K. ***Uracil-DNA Glycosylase Produces Excess Lethal Damage Induced by an Auger cascade in BrdU-labelled Bacteriophage T1.*** Int. J. Radiat. Biol.: **64(2)**: 157-164: 1993.

Kobayashi, K., Frohlich, H., Usami, N., Takakura, K., Le Sech, C. ***Enhancement of X-Ray-Induced Breaks in DNA Bound to Molecules Containing Platinum: A Possible Application to Hadrontherapy.*** Radiation Research: **157**: 32-37: 2002.

Solberg, T. D., Iwamoto, K. S., Norman, A. ***Calculation of Radiation Dose Enhancement Factors for Dose Enhancement Therapy of Brain Tumours.*** Phys. Med. Biol.: **37(2)**: 439-443: 1992  
(Printed in the UK).

Usami, N., Kobayashi, K., Maezawa, H., Hieda, K., Ishizaka, S. ***Biological Effects of Auger Processes of Bromine on Yeast Cells Induced by Monochromatic Synchrotron X-rays.*** Int. J. Radiat. Biol.: **60(5)**: 757-768: 1991.

Wachter, E., Dees, C., Harkins, J. Fisher, W. Scott, T. ***Imaging Photosensitizer Distribution and Pharmacology using Multiphoton Microscopy.*** <http://www.photogen.com>.

## DRUGS

Ando, M., Minami, H., Ando, Y., Saka, H., Sakai, S., Yamamoto, M., Sasaki, Y., Shimokata, K., Hasegawa, Y. ***Multi-institutional Validation Study of Carbonplatin Dosing Formula Using Adjusted Serum Creatinine Level.*** Clinical Cancer Research: **6**: 4733-4738: December 2000.

Boudou, C., Ferrero, C., Estève, F., Elleaume, H. ***Calculation of Radiation Dose for Synchrotron Stereotactic Radiotherapy of Brain Tumours.*** MCNEG Mtg: 1-12: April 2005.

Brabec, V., Kasparkova, J. ***Molecular Aspects of Resistance to Antitumor Platinum Drugs.*** Drug Resistance Updates: **5**:147-161: 2002.

Canadian Centre for Occupational Health and Safety. **Rose Bengal Toxicity.** MDL Information Systems, Inc.: 2003-3: August 2003.

Etienne, M. C., Leger, F., Pivot, X., Chatelut, E., Bensadoun, R. J., Guardiola, E., Renée, N., Magné, N., Canal, P., Milano, G. ***Pharmacokinetics of Low-Dose Carboplatin and Applicability of a Method of Calculation for Estimating Individual Drug Clearance.*** Annals of Oncology: 14: 643-647: 2003.

Ilinski, P., Lai, B., Cai, Z., Yun, W., Legnini, D., Talarico, T., Cholewa, M., Webster, L. K., Deacon, G. B., Rainone, S. Phillips, D. R., Stampfi, A. P. J. ***The Direct Mapping of the Uptake of Platinum Anticancer Agents in Individual Human Ovarian Adenocarcinoma Cells Using a Hard X-ray Microprobe.*** Cancer Research: 63: 1776-1779: April 15, 2003.

Kinsella, T. J., Vielhuber, K. A., Kunugi, K. A., Schupp, J., Davis, T. W., Sands, H. ***Preclinical Toxicity and Efficacy Study of a 14-day Schedule of Oral 5-Iodo-2-pyrimidinone-2'-deoxyribose as a Prodrug for 5-Iodo-2' deoxyuridine Radiosensitization in U251 Human Glioblastoma Xenografts<sup>1</sup>.*** Clin Cancer Res 2000: 6:1468-1475: April 2000.

Kobayashi, K., Usami, N., Sasaki, I., Frohlich, H., Le Sech, C. ***Study of Auger Effect in DNA When Bound to Molecules Containing Platinum. A Possible Application to Hardrontherapy.*** J. Nucl. Instr. And Meth. In Phys. Res. B.: 199: 348-355: 2003.

Mishima, M., Samimi, G., Kondo, A., Lin, X., Howell, S. B. ***The Cellular Pharmacology of Oxaliplatin Resistance.*** Eur. J. of Cancer: 38: 1405-1412: 2002.

Paulwels, B., Korst, A. E. C., Andriessen, V., Baay, M. F. D., Pattyn, G. G. O., Lambrechts, H. A. J., De Pooter, C. M. J., Lardon, F., Vermorcken, J. B. ***Unraveling the Mechanism of Radiosensitization by Gemcitabine: The Role of TP53.*** Radiation Research: 164: 642-650: 2005.

Sedelnikova, O., Luu, A., Karamychev, V., Panyutin, I. G., Neumann, R. D. ***Development of DNA-based Radiopharmaceuticals Carrying Auger-electron Emitters for Antigene Radiotherapy.*** Int. J. Radiation Oncology Biol. Phys.: 49(2): 391-396: 2001.

Urien, S., Brain, E., Bugat, R., Pivot, X., Lochon, I., Vauzelle, M. L., Lokiec, F. ***Pharmacokinetics of Platinum After Oral or Intravenous Cisplatin: A Phase 1 Study in 32 Adult Patients.*** Cancer Chemother Pharmacol: 55: 55-60: 2005.

Welters, M. J. P., Fichtinger-Schepman, A. M. J., Baan, R. A., Hermsen, M. A. J. A., van der Vugh, W. J. F., Cloos, J., Braakhuis, B. J. M. ***Relationship between the Parameters Cellular Differentiation, Doubling Time and Platinum Accumulation and Cisplatin Sensitivity in a Panel of Head and Neck Cancer Cell Lines.*** Int. J. Cancer: 71:410-415: 1997.

## HUMAN PROTOCOLS: BRAIN TUMORS

Carde, P., Timmerman, R., Mehta, M. P., Koprowski, C. D., Ford, J., Tishler, R. B., Miles, D., Miller, R. A., Renschler, M. F. **Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients with Brain Metastases.** J Clin Oncol: 19(7): 2074-2083: April 1, 2001.

Jacobs, S. S., Fox, E., Dennie, C., Morgan, L. B., McCully, C. L., Balis, F. M. **Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates.** Clin Cancer Res: 11: 1669-1674: February 15, 2005.

Kry, S. F., Salehpour, M., Followill, D. S., Stovall, M., Kuban, D., White, R. A., Rosen, I. I. **The Calculated Risk of Fatal Secondary Malignancies from Intensity-Modulated Radiation Therapy.** Int. J. Radiation Oncology Biol. Phys.: 62(4): 1195-1203: 2005.

Mehta, M. P., Shapiro, W. R., Glantz, M. J., Patchell, R. A., Weitzner, M. A., Meyers, C. A., Schultz, C. J., Roa, W. H., Leibenhaut, M., Ford, J., Curran, W., Phan, S., Smith, J. A., Miller, R. A., Renschler, M. F. **Lead-in Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients with Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points.** Journal of Clinical Oncology: 20(16): 3445-3453: August 15, 2002.

Mehta, M. P., Rodrigus, P., Terhaard, C. H. J., Roa, A., Suh, J., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M., Komaki, R., Schultz, C., Timmerman, R., Curran, W., et al. **Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases.** J. Clin Oncol: 21(13): 2529-2536: July 1, 2003.

Meyers, C. A., Smith, J. A., Bezjak, A., Mehta, M. P., Liebmann, J., Illidge, T., Kunkler, I., Caudrelier, J. M., Eisenberg, P. D., Meerwaldt, J., Siemers, R., Carrie, C., Gaspar, L. E., et al. **Neurocognitive Function and Progression in Patients with Brain Metastases Treated with Whole-brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial.** Journal of Clinical Oncology: 22(1): 157-165: January 1, 2004.

**Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults with Newly Diagnosed Glioblastoma Multiforme.** NCI's Cancer Information: <http://cancertrials.nci.nih.gov>: January 21, 2005.

Principal Investigator: Dr. Pipas. **Pilot Study to Measure Brain Tissue/Tumor Concentration of Oxaliplatin in Patients with High Grade Gliomas.** Norris Cotton Cancer Center (DHMC) Clinical Trial: 2006.

University of California, San Francisco. **Brain Tumor Center Update.** UCSF Cancer Center UCSF Brain Tumor Program: Department of Neurological Surgery & Brain Tumor research Center.

## HUMAN PROTOCOLS: GI CANCERS

Bécouran, Y., Agostini, C., Trufflandier, N., Boulanger, V. ***Oxaliplatin: Available Data in Non-colorectal Gastrointestinal Malignancies.*** Critical Review in Oncology/Hematology: 40: 265-272: 2001.

Braun, A. H., Achterrath, W., Wilke, H., Vanhoefer, U., Harstrick, A., Preusser, P. ***New Systemic Frontline Treatment for Metastatic Colorectal Carcinoma.*** Cancer: 100(8): 1558-1577: April 15, 2004.

Dawson, L. A., McGinn, C. J., Lawrence, T. S. ***Conformal Chemoradiation for Primary and Metastatic Liver Malignancies.*** Seminars in Surgical Oncology: 21: 249-255:2003.

Francis, D. L., Visvikis, D., Costa, D. C., Arulampalam, T. H. A., Townsend, C., Luthra, S. K., Taylor, I., Ell, P. J. ***Potential Impact of [<sup>18</sup>F]3'-fluorothymidine versus [<sup>18</sup>F]fluoro-2-deoxy-D-glucose in Positron Emission Tomography for Colorectal Cancer.*** Eur J. Nucl Med Mol Imaging: 30: 988-994: 2003.

Johnson, P. J. ***Systemic Chemotherapy of Liver Tumors.*** Seminars in Surgical Oncology: 19: 116-124: 2000.

Maurel, J., Cervantes, A., Conill, C., Salazar, R., Martin-Richard, M., Pera, M., Manzano, H., Chirivella, I., Gallego, R., Marfa, X. ***Phase I Trial of Oxaliplatin in Combination with Cisplatin, Protated-infusion Fluorouracil, and Radiotherapy in Advanced Esophageal and Gastroesophageal Carcinoma.*** Int. J. Radiation Oncology Biol. Phys.: 62(1): 91-96:2005.

Schelthauer, W., Kornek, G., Ulrich-Pur, H., Penz, M., Raderer, M., Salek, T., Halder, K., Kwasny, W., Depsch, D. ***Oaxliplatin plus Raltitrexed in Patients with Advanced Colorectal Carcinoma. Results of a Phase I-II Trial.*** Cancer: 91(7): 1264-1271: April 1, 2001.

Vuong, T., Szego, P., David, M., Evans, M., Parent, J., Mayrand, S., Corns, R., Burtin, P., Faria, S., Devic, S. ***The Safety and Usefulness of High-Dose-Rate Endoluminal Brachytherapy as a Boost in the Treatment of Patients with Esophageal Cancer with External Beam Radiation with or without Chemotherapy.*** Int. J. Radiation Oncology Biol. Phys.: 63(3): 758-764: 2005.

Zhao, K., Shi, X., Jiang, G., Yao, W., Guo, X., Wu, G., Zhu, L. ***Late Course Accelerated Hyperfractionated Radiotherapy Plus Concurrent Chemotherapy for Squamous Cell Carcinoma of the Esophagus: A Phase III Randomized Study.*** Int. J. Radiation Oncology Biol. Phys.: 62(4): 1014-1020: 2005.

## HUMAN PROTOCOLS: HEAD AND NECK.

Al-Amro, A., Al-Rajhi, N., Khafaga, Y., Memon, M., Al-Hebshi, A., El-Enbabi, A., El-Husseiny, G., Radawi, A., Belal, A., Allam, A., El-Sebaie, M. **Neoadjuvant Chemotherapy Followed by Concurrent Chemo-radiation therapy in Locally Advanced Nasopharyngeal Carcinoma.** Int. J. Radiation Oncology Biol. Phys.: 62(2): 508-513: 2005.

Isobe, K., Uno, T., Aruga, T., Kawakami, H., Ueno, N., Hanazawa, T., Okamoto, Y., Ito, H. **Weekly Cisplatin Administration Concurrent with Radiation Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma.** Int. J. Clin Oncol: 10: 201-203: 2005.

Johnson, F. M., Garden, A. S., Palmer, J. L., Shin, D. M., Morrison, W., Papadimitrakopoulou, V., Khuri, F., Clayman, G., Goepfert, H., Ang, K. K., Hong, W. K., Glisson, B. S. **A Phase I/II Study of Neoadjuvant Chemotherapy Followed by Radiation with Boost Chemotherapy for Advanced T-stage Nasopharyngeal Carcinoma.** Int. J. Radiation Oncology Biol. Phys.: 63(3): 717-724: 2005.

Katori, H., Tsukuda, M. **Comparison of Induction Chemotherapy with Docetaxel, Cisplatin, and 5-fluorouracil (TPF) Followed by Radiation Vs Concurrent Chemoradiotherapy and with TPF in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.** Clinical Oncology: 17: 148-152: 2005.

## HUMAN PROTOCOLS: LUNG CANCER.

Halter, G., buck, A. K., Schirrmeister, H., Wurziger, I., Liewad, F., Glatting, G., Neumaier, B., Sunder-Plassmann, L., Reske, S. N., Hetzel, M. **[<sup>18</sup>F] 3-deoxy-3'-fluorothymidine Positron Emission Tomography: Alternative or Diagnostic Adjunct to 2-[<sup>18</sup>F]-fluoro-2-deoxy-D-glucose Positron Emission Tomography in the Workup of Suspicious Central Focal Lesions?** J Thorac Cardiovasc Surg: 127(4): 1093-1099: 2004.

Keene, K. S., Harman, E. M., Knauf, D. G., McCarley, D., Zlotecki, R. A. **Five-Year Results of a Phase II Trial of Hyperfractionated Radiotherapy and Concurrent Daily Cisplatin Chemotherapy for Stage III Non-Small-Cell Lung Cancer.** Am J Clin Oncol: 28: 217-222: 2005.

Kim, Y. S., Yoon, S. M., Choi, E. K., Yi, B. Y., Kim, J. H., Ahn, S. D., Lee, S., Shin, S. S., Lee, J. S., Suh, C., Kim, S., Kim, D. S., Kim, W. S. **Phase II Study of Radiotherapy with Three-Dimensional Conformal boost Concurrent with Paclitaxel and Cisplatin for Stage IIIB Non-Small-Cell Lung Cancer.** Int. J. Radiation Oncology Biol. Phys.: 62(1): 76-81: 2005.

Komaki, R., Swann, R. S., Ettinger, D. S., Glisson B. S., Sandler, A. B., Movsas, B., Suh, J., Byhardt, R. W. **Phase I Study of thoracic Radiation Dose Escalation with Concurrent Chemotherapy for Patients with Limited Small-Cell Lung Cancer: Report of Radiation Therapy Oncology Group (RTOG) Protocol 97-12.** Int. J. Radiation Oncology Biol. Phys.: 62(2): 342-350: 2005.

Schild, S. E., Wong, W. W., Vora, S. A., Halyard, M. Y., Northfelt, D. W., Kogut, H. L., Wheeler, R. H. ***The Long-Term Results of a Pilot Study of Three Times a Day Radiotherapy and Escalating Doses of Daily Cisplatin for Locally Advanced Non-Small-Cell Lung Cancer.*** Int. J. Radiation Oncology Biol. Phys.: 62(5): 1432-1437: 2005.

## **HUMAN PROTOCOLS: PANCREATIC CANCER**

Dicker, A., Abrams, R. A. ***Radiochemotherapy in the Management of Pancreatic Cancer – Part II: Use in Adjuvant and Locally Unresectable Setting.*** Semin Radiat Oncol: 15: 235-244: 2005.

Kawakami, H., Uno, T., Isobe, K., Ueno, N., Aruga, T., Sudo, K., Yamaguchi, T., Saisho, H., Kawata, T., Ito, H. ***Toxicities and Effects on Involved-Field Irradiation with Concurrent Cisplatin for Unresectable Carcinoma of the Pancreas.*** J. Radiation Oncology Biol. Phys.: 62(5): 1357-1362: 2005.

Mornex, F., Girard, N., Delpero, J. R., Partensky, C. ***Radiochemotherapy in the Management of Pancreatic Cancer – Part I: Neoadjuvant Treatment.*** Semin Radiat Oncol: 15: 226-234: 2005.

Symon, Z., Davis, M., McGinn, C. J., Zalupski, M. M., Lawrence, T. S. ***Concurrent Chemoradiotherapy with Gemcitabine and Cisplatin for Pancreatic Cancer: From the Laboratory to the Clinic.*** Int. J. Radiation Oncology Biol. Phys.: 53(1): 140-145: 2002.

Wilkowski, R., Thoma, M., Dühmke, E., Rau, H. G., Heinemann, V. ***Concurrent Chemoradiotherapy with Gemcitabine and Cisplatin After incomplete (R1) Resection of Locally Advanced Pancreatic Carcinoma.*** Int. J. Radiation Oncology Biol. Phys.: 58(3): 768-772: 2004.

In the following table are some of the protocols currently being used at various medical centers around the world are included as general information as to tumor types, drug, drug doses, radiation dose, and schedules.

Protocol	Drug	Dose	Schedule for drug	Schedule for RadRx/start time rel. to drug	Rad dose	Tumor type	Institution	Type of study	Author
Abdominopelvic Rad after Surg. And chemo	Pt Carboplatin	135 mg/m <sup>2</sup>	6 cycles one mo. postop	1 Gy/day	23 Gy	Ovarian epithelial	Toronto Princess Marg. Hosp.	4 yr followup	Dinniwell
Preop chemo plus rad or Sq.cell	Pt Cis-platinum	20 mg/m <sup>2</sup>	On days 1-4 and 21-24	1.8 Gy/day	45Gy	Squamous cell head and neck	unknown	18 Pts.	Slotman
NeoChemo plus rad with boost chemo	Pt Cis-platinum/5FU	100 mg/m <sup>2</sup> day 1 then 80/day	3 cycles every 3 wks.	Start 3-4 wks after chemo 2 Gy/day	70 Gy	Nasopharyngeal Ca	MD Anderson	Phase I/II	Johnson
NeoChemo plus chemo/Rad	Pt Cis-platinum/epirubicin	100 mg/m <sup>2</sup> plus boost 25/day	Day 1, 21, then for 4 days beginning on days 42,63,84	2 Gy/day	66 Gy	Nasopharyngeal Ca	King Faisal	110 pts.	Al-Amro
T.i.d. radRx with increasing doses of chemo	Pt Cis-platinum	7.5 mg/m <sup>2</sup> /day	For 12 days	1.5 to 1.8 Gy/t.i.d./day	57.6 Gy	Non-small cell lung	Mayo Clinic	Phase I	Schild
RadRx with 3-D boost	Pt Cis-platinum/paclitaxel	20 mg/m <sup>2</sup> plus 40mg. paclit.	Weekly for 8 weeks	1.8 Gy/day	70.2 Gy	Non-small cell lung	Asan Med Ctr Seoul	Phase II	Kim
RadRx Oncol group Protocol 97-12	Pt Cis-platinum/etoposide	60 mg/m <sup>2</sup> plus etoposide 120mg/m <sup>2</sup>	Days 1-3	1.8 gy/day	50.4-64.8 Gy	Small cell Ca lung	MD Anderson	Phase I	Komaki
Double Pt agents with 5FU	Pt Oxaliplatin with Cis-platinum	85 mg/m <sup>2</sup> oxali. , 55mg/m <sup>2</sup> cis	Days 1 and 29	1.8 Gy/day	50.4 Gy	Esophageal and Gastroesophageal	ICMHO Clinic Spain	Phase I	Maurel
Hyperfrac.Ra dRx and chemo	Pt Cis-platinum/5fu	25 mg/m <sup>2</sup>	Day 1-3 every 4 weeks	1.8 – 3.0 Gy/day	68.4 Gy	Squamous cell esophagus	Fudan Ca hosp. China	Phase III	Zhao

Protocol	Drug	Dose	Schedule for drug	Schedule for RadRx/start time rel. to drug	Rad dose	Tumor type	Institution	Type of study	Author
Egf radrx and chemo	Pt Cis-platinum	various	various	various	various	Bladder Ca	Mass General	4 different trials combined	Chakravarti
Radrx and chemo	Pt Cis-platinum	5mg/m2	Daily all during radrx	1.8-2.0 Gy/day	50.4 Gy	Ca pancreas	Chiba Japan	33 patients	Kawakami
Pharmacokinetics	Pt Carboplatin	50 mg/m2/day IV 2 days a week	Days 1 &4 for 7 weeks	2 Gy/day	70 Gy	Head and neck	Nice France	31 patients	Etienne
Chemo and rad concurrent	Pt Cisplatin and gemcitabine	30 mg/m2 with 300 mg/m2 gemcit.	Days 1,8,22,29. Then 50mg/m2 and 1000 mg. gem. Days 1 and 15 on 4 wk cycles	Concurrent rad Rx as 1.8 Gy/day	45-50 Gy	Ca pancreas	Munich, Germany	30 pts.	Wilkowski

## HUMAN PROTOCOLS: GENERAL

Chakravarti, A., Winter, K., Wu, C. L., Kaufman, D., Hammond, E., Parliament, M., Tester, W., Hagan, M., Grignon, D., Heney, N., Pollack, A., Sandler, H., Shipley, W. ***Expression of the Epidermal Growth Factor Receptor and Her-2 are Predictors of Favorable Outcome and Reduced Complete Response Rates, Respectively, in Patients with Muscle-Involving Bladder Cancers Treated by Concurrent Radiation and Cisplatin-Based Chemotherapy: A Report from the Radiation Therapy Oncology Group.*** Int. J. Radiation Oncology Biol. Phys.: **62(2):** 309-317: 2005.

Crookart, N., Jordan, B. F., Baudelet, C., Ansiaux, R., Sonveaux, P., Grégoire, V., Beghein, N., DeWever, J., Bouzin, C., Feron, O., Gallez, B. ***Early Reoxygenation in Tumors after Irradiation: Determining Factors and Consequences for Radiotherapy Regimens Using Daily Multiple Fractions.*** Int. J. Radiation Oncology Biol. Phys.: **63(3):** 901-910: 2005.

Delaunoy, T., Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Findlay, B. P., Thomas, S. P., Salim, M., Schaefer, P. L., Stella, P. J., Green E., Mailliard, J. A. ***Mortality Associated with Daily Bolus 5-Fluorouracil/Leucovorin Administered in Combination with Either Irinotecan or Oxaliplatin. Results from Intergroup Trial N9741.*** Cancer: **101:** 2170-2176: 2004.

Dinniwell, R., Lock, M., Pintilie, M., Fyles, A., Laframboise, S., Depetrillo, D., Levin, W., Manchul, L., Murphy, J., Oza, A., Rosen, B., Sturgeon, J., Milosevic, M., ***Consolidative Abdominopelvic Radiotherapy After Surgery and Carboplatin/Paclitaxel Chemotherapy for Epithelial Ovarian Cancer.*** Int. J. Radiation Oncology Biol. Phys.: **62(1):** 104-110:2005.

Eng, T. Y., Thomas, Jr., C. R., Herman, T. S. ***Primary Radiation Therapy for Localized Prostate Cancer.*** Urologic Oncology: **7:** 239-257: 2002.

Goetein, M. ***The Cell's-Eye View: Assessing Dose in Four Dimensions.*** Int. J. Radiation Oncology Biol. Phys.: **62(4):** 951-953: 2005.

Hawkins, R. B. ***The Influence of Concentration of DNA on the Radiosensitivity of Mammalian Cells.*** Int. J. Radiation Oncology Biol. Phys.: **63(2):** 529-535: 2005.

Joubert, A., Biston, M. C., Boudou, C., Ravanat, J. L., Brochard, T., Charvet, A. M., Estève, F., Balosso, J., Foray, N. ***Irradiation in Presence of Iodinated Contrast Agent Results in Radiosensitization of Endothelial Cells: Consequences for Computed Tomography Therapy.*** Int. J. Radiation Oncology Biol. Phys.: **62(5):** 1486-1496: 2005.

Ma, B. B. Y., Bristow, R. B. Kim, J., Siu, L. L. ***Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents.*** J Clin Oncol: **21:** 2760-2776:2003.

Mesa, A. V., Norman, A., Solberg, T. D., Demarco, J. J., Smathers, J. B. ***Dose Distribution Using Kilovoltage X-rays and Dose Enhancement from Iodine Contrast Agents.*** Phys. Med. Biol.: 44: 1955-1968: 1999 (Printed in the UK).

Raju, U., Ariga, H., Dittmann, K., Nakata, E., Ang, K. K., Milas, L. ***Inhibition of DNA Repair as a Mechanism of Enhanced Radioresponse of Head and Neck Carcinoma Cells by a Selective Cyclooxygenase-2 Inhibitor, Celecoxib.*** Int. J. Radiation Oncology Biol. Phys.: 63(2): 520-528: 2005.

Scarantino, C. W., Rini, C. J., Aquino, M., Carrea, T. B., Ornitz, R. D., Anscher, M. S., Black, R. D. ***Initial Clinical Results of an In Vivo Dosimeter During External Beam Radiation Therapy.*** Int. J. Radiation Oncology Biol. Phys.: 62(2): 606-613: 2005.

Wagner, M., Seitz, U., Buck, A., Neumaier, B., Schultheiß, S., Bangerter, M., Bommer, M., Leithäuser, F., Wawra, E., Munzert, G., Reske, S. N. ***3'-[<sup>18</sup>F]Fluoro-3'-Deoxythymidine ([<sup>18</sup>F]-FLT) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease.*** Cancer Research: 63: 2681-1687: May 15, 2003.

## PEDIATRIC USE

Armstrong, C. L., Gyato, K., Awadalla, A. W., Lustig, R., Tochner, Z. A. ***A Critical Review of the Clinical Effects of Therapeutic Irradiation Damage to the Brain: The Roots of Controversy.*** Neuropsychology Review: 14(1): 65-86: March 2004.

Chuba, P. J., Aronin, P., Bhambhani, K., Elchenhorn, M., Zamarano, L., Clancy, P., Muhlbauer, M., Porter, A. T., Fontanesi, J. ***Hyperbaric Oxygen Therapy for Radiation-Induced Brain Injury in Children.*** Cancer: 80(10): 2005-2012: 1997.

Knight, K. R., G., Kraemer, D. F., Neuwelt, E. A. ***Ototoxicity in Children Receiving Platinum Chemotherapy: Understanding a Commonly Occurring Toxicity that May Influence Academic and Social Development.*** J Clin Oncol: 23(34): 8588-8596: December 1, 2005.

Middleton, J. A. ***Brain Injury in Children and Adolescents.*** APT: 7: 257-265: 2001.

Oi, S., Kokunai, T., Ijichi, A., Matsumoto, S., Raimondi, A. J. ***Radiation-Induced Brain Damage in Children – Histological Analysis of Sequential Tissue Changes in 34 Autopsy Cases.*** Neurol Med Chir (Tokyo): 30: 36-42: 1990.

## GENERAL

Boswell, C. A., Brechbiel, M. W. **Auger Electrons: Lethal, Low Energy, and Coming Soon to a Tumor Cell Nucleus near You.** J Nucl Med.: 46(12): 1946-1947: December 2005.

Boudaïffa, Badia; Cloutier, Pierre; Hunting, Darel; Huels, Michael A.; Sanche, Léon **Resonant Formation of DNA Strand Breaks by Low-Energy (3 to 20 eV) Electrons.** Science 287: 1658-1660: 3 March 2000.

Boulikas, T., Bougiouka, M. **Recent Clinical Trials Using Cisplatin, Carboplatin and Their combination Chemotherapy Drugs (Review).** Oncology Reports: 11: 559-595: 2004.

Brenner, D. J. **Induced Second Cancers After Prostate-Cancer Radiotherapy: No Cause for Concern?** Int. J. Radiation Oncology Biol. Phys.: 65(3): 637-639: 2006.

Buchegger, F., Perillo-Adamer, F., Dupertuis, Y. M., Delaloye, A. B. **Auger Radiation Targeted into DNA: A Therapy Perspective.** Eur J Nucl Med Mol Imaging: 33: 1352-1363: 2006.

Carroll, Frank E. **Tunable Monochromatic X Rays: A New Paradigm in Medicine.** ; AJR 179:583-590, September 2002.

Carroll, F. **Tunable, Monochromatic X-Rays: An Enabling Tehcnology for Molecular/Cellular Imaging and Therapy.** Journal of Cellular Biochemistry: 90: 502-508: 2003.

Carroll, F. E., Mendenhall, M. H., Traeger, R. H., Brau, C., Waters, J. W. **Pulsed Tunable Monochromatic X-Ray Beams from a Compact Source: New Opportunities.** AJR 181:1197-1202, November 2003.

Corde, S., Joubert, A., Adam, J. F., Charvet, A. M., Le Bas, J. F., Estève, F., Elleaume, H., Baloss, J. **Synchrotron Radiation-Based Experimental Determination of the Optimal Energy for Cell Radiotoxicity Enhancement Following Photoelectric Effect on Stable Iodinated Compounds.** British Journal of Cancer: 91: 544-551: 2004.

Goorley, T., Zamenhof, R., Nikjoo, H. **Calculated DNA Damage from Gadolinium Auger Electrons and Relation to Dose Distributions in a Head Phantom.** Int. J. Radiat. Biol.: 80(11): 933-940: November-December 2004.

Hall, E. J., Phil, D. **Intensity-Modulated Radiation Therapy, Protons, and the Risk of Second Cancers.** Int. J. Radiation Oncology Biol. Phys.: 65(1): 1-7: 2006.

- Hartemann, F. V. Baldis, H. A., Kerman, A. K., Le Foll, A., Luhmann, Jr., N. C., Rupp, B. **Three-Dimensional Theory of Emittance in Compton Scattering and X-ray Protein Crystallography.** PhysRevE 64(1): 016501-016526:2001.
- Hartemann, F. V., Le Foll, A., Kerman, A. K., Rupp, B., Gibson, D. J., Landahl, E. C., Troha, A. L., Luhmann, Jr., N. C., Baldis, H. A. **Three Dimensional Theory of Emittance in Compton Scattering.** American Institute of Physics: 0-7354-0005-9: 450-464: 2001.
- Heinäsmäki, S. **Decay of Coherently Excited States Produced by Photon-Electron and Electron-Electron interactions: Effects on Angular Distributions.** J. Electron Spectrosc. Relat. Phenom.: 114-116: 75-80: 2001.
- Karnas, S. J. Moiseenko, V. V., Yu, E., Truong, P., Battista, J. J. **Monte Carlo Simulations and Measurement of DNA Damage from X-Ray-Triggered Auger Cascades in Iododeoxyuridine (IUdR).** Radiat Environ Biophys: 40: 199-206: 2001.
- Karnas, S. J., Yu, E., McGarry, R. C., Battista, J. J. **Optimal Photon Energies for IUdR K-edge Radiosensitization with Filtered X-ray and Radioisotope Sources.** Phys. Med. Biol.: 44: 2537-2549: 1999 (Printed in the UK).
- Kassis, A. I. **Toxicity and Therapeutic Effects of Low-Energy Electrons.** Nucl. Instr. and Meth. in Phys. Res. B: 87: 279-284: 1994.
- Kasis, A. I. **Cancer Therapy with Auger Electrons: Are We Almost There?** J Nucl Med.: 44(9):1479 -1481: Septemer 2003.
- Kereiakes, J. G., Rao, D. V., Sastry, K. S. R., Howell, R. W. **AAPM Report No. 37 Auger Electron Dosimetry.** Medical Physics: 19(6): 1992.
- Levin, J. C., Armen, G. B. **Studies of Fluorescence and Auger Decay Following Inner-Shell Photoionization.** Radiation Physics and Chemistry: 70: 105-121: 2004.
- Pauwels, B., Korst, A. E. C., Andriessen, V., Baay, M. F. D., Pattyn, G. G. O., Lambrechts, H. A. J., De Pooter, C. M. J., Lardon, F., Vermorken, J. B. **Unraveling the Mechanism of Radiosensitization by Gemcitabine: The Role of TP53.** Radiat. Res.: 164: 642-650: 2005.
- Pignol, J. P., Rakovitch, E., Beachey, D., Le Sech, C. **Clinical Significance of Atomic Inner Shell Ionization (ISI) and Auger Cascade for Radiosensitization Using IUdR, BUdR, Platinum Salts or Gadolinium Porphyrin Compounds.** Int. J. Radiation Oncology Biol. Phys.: 55(4): 1082-1091: 2003.
- Roa, W. H. Y., Miller, G. G., McEwan, A. J. B., McQuarrie, S. A., Tse, J., Wu, J. Wiebe, L. I. **Targeted Radiotherapy of Multicell Neuroblastoma spheroids with High Specific Activity [<sup>125</sup>I]Meta-Iodobenzylguanidine.** Int. J. Radiation Oncology Biol. Phys.: 41(2): 425-432: 1998.

Schlathölter, T., Alvarado, F., Hoekstra, R. ***Ion-Biomolecule Interactions and Radiation Damage.*** Nucl. Instr. and Meth. in Phys. Res. B:233:62-69:2005.

Ünak, T., Ünak, P., Ongun, B., Duman, Y. ***Synthesis and Iodine-125 Labelling of Glucuronide Compounds for combined Chemo- and Radiotherapy of Cancer.*** Appl. Radiat. Isot.: 48(6): 777-783 1997. (Printed in Great Britain)

Verhaegen, F., Reniers, R., Deblois, F., Devic, S., Seuntjens, J., Hristov, D. ***Dosimetric and Microdosimetric Study of Contrast-Enhanced Radiotherapy with Kilovolt X-rays.*** Phys. Med. Biol.: 50: 3555-3569:2005.

Watt, D. E. ***Some Current Advances in Biophysical Applications of Ionizing Radiation for Health Preservation.*** Nucl. Instr. and Meth. in Phys. Res. A: 255: 298-305: 1987.